<DOC>
	<DOCNO>NCT02193334</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled Phase I/II study design evaluate safety efficacy KP-100IT , code Hepatocyte Growth Factor ( HGF ) formulation intrathecal injection , treatment acute spinal cord injury . The study conduct two clinical site Japan .</brief_summary>
	<brief_title>Phase I/II Study KP-100IT Acute Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Age equal great 18 year equal less 75 year Cervical spinal cord injury , Grade A , B1 B2 modify Frankel Scale 72 hour since injury Subjects able provide write informed concent , may require relative sign arm/hand function subject compromise Spinal cord injury C1C2 0r C2C3 level Patients able start rehabilitation within week setup respirator reason First dose study drug give within 78 hour since injury History spinal cord injury abnormality spinal cavity . Or current considerable meningeal damage Outcome assessment conduct adequately damage injury injury Highdose steroid therapy within 30 day entry Patients diseases serious liver disorder , renal disorder , hear disease , blood dyscrasia , metabolism disorder infection History malignant tumor Patients participate clinical study within 30 day entry Patients allergies drug schedule use study Administration study drug area spinal cord injury appropriate example intrathecal infection intrathecal tumor Patients able understand `` informed consent '' properly Patients nursing may pregnant Investigator considers patient appropriate participating study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hepatocyte Growth Factor</keyword>
	<keyword>HGF</keyword>
	<keyword>KP-100IT</keyword>
	<keyword>Intrathecal injection</keyword>
</DOC>